Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05556096 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

A Phase 3 study of Generalized Myasthenia Gravis, sponsored by Alexion Pharmaceuticals.

Active
Registry status
Phase 3
Development phase
261
Enrollment target
20
Study locations

NCT05556096 is a Phase 3 study of Generalized Myasthenia Gravis that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 261 participants, above the 121-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (116% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05556096, a Phase 3 study of Generalized Myasthenia Gravis, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
261 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

Conditions Studied

Generalized Myasthenia Gravis

Interventions

  • COMBINATION_PRODUCT Placebo
  • COMBINATION_PRODUCT ALXN1720

Study Locations (20)

Florida

  • Research Site - Bradenton
  • Research Site - Maitland
  • Research Site - Tampa

Georgia

  • Research Site - Augusta
  • Research Site - Gainesville
  • Research Site - Savannah

New York

  • Research Site - Patchogue
  • Research Site - Rochester
  • Research Site - Syracuse

Michigan

  • Research Site - Detroit
  • Research Site - East Lansing

California

  • Research Site - Orange

Colorado

  • Research Site - Fort Collins

District of Columbia

  • Research Site - Washington D.C.

Illinois

  • Research Site - Springfield

Trial Details

FieldValue
Enrollment Target 261 participants
Start Date 2022-11-21
Est. Completion 2027-08-31
Phase Phase 3

Sponsor

Alexion Pharmaceuticals

162 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05556096

The ClinicalTrials.gov registry entry for NCT05556096 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 261 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 121-participant average among 26 other Generalized Myasthenia Gravis trials with a reported enrollment target (116% higher). The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05556096 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Georgia, New York.

Frequently Asked Questions

What is clinical trial NCT05556096 about?

NCT05556096 is a clinical study titled "Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis". The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

What is the current status of trial NCT05556096?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 261 participants. The study started on 2022-11-21. Estimated completion is 2027-08-31.

What conditions does trial NCT05556096 study?

This clinical trial studies the following conditions: Generalized Myasthenia Gravis.

What interventions are being tested in trial NCT05556096?

The interventions under investigation include: Placebo (COMBINATION_PRODUCT), ALXN1720 (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05556096?

This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05556096 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Generalized Myasthenia Gravis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Generalized Myasthenia Gravis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.